Arine Valuation, Funding & Investors

Arine is valued at $520M as of May 2025.

See full Arine profile

Last Arine valuation

$520M

Series C · May 2025

Last Arine funding round

$30M

Series C · May 2025

Cumulative funding Arine raised

$70M

across 3 funding rounds

Key investors in Arine

  • Katalyst Ventures
  • 111° West Capital
  • New Leaf Venture Partners
  • Kaiser Permanente Ventures
  • Town Hall Ventures
  • MBX Capital

Arine Overview

About Arine

Arine is a San Francisco-headquartered medication management platform that uses data analytics to detect risks in patient prescriptions and prevent adverse events. The service integrates with pharmacy systems to review drug interactions, dosages, and adherence, supporting clinicians in optimizing therapies for chronic conditions like diabetes and hypertension.


Founded

2017

HQ

United StatesSan Francisco, CA

Website

arine.io

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$520M (May 2025)

Arine Valuation

Arine is currently valued at $520M, based on its Series C in May 2025.

The $30M round was led by Town Hall Ventures, with participation from Kaiser Permanente Ventures.

Arine's valuation has grown 8.1x from $64M at its Series A in January 2021 to $520M in May 2025, across 2 priced rounds.

Arine valuation by funding round

Arine valuation by funding round
DateStageValuation
May 2025Series C$520M
Jan 2021Series A$64M

Arine Funding History

Arine has raised a total of $70M across 3 funding rounds.

Arine's first fundraising round was a $11M Series A in January 2021. The most recent completed round was a $30M Series C in May 2025.

Arine funding rounds

Arine funding rounds
DateStageInvestorsRaisedValuationDeal Summary
May 2025Series CTown Hall Ventures (lead); Kaiser Permanente Ventures$30M$520MArine is a San Francisco-based AI-driven healthcare SaaS platform specializing in medication intelligence and optimization. It helps health plans and risk-bearing providers deliver personalized therapy solutions using large datasets to identify patients, recommend interventions, and measure outcomes, aiming to improve patient results and reduce costs amid financial and regulatory pressures in healthcare. Arine raised $30 million in its Series C funding round in June 2025, led by Town Hall Ventures with participation from Kaiser Permanente Ventures and existing investors, bringing total funding to $66 million. The funds will support expansion in specialty pharmacy management, enhance AI automation for routine tasks, deepen data integration for personalized therapy, and broaden market reach to advance value-based care. The platform has demonstrated strong traction, achieving over 10% total cost savings and more than 40% reduction in hospitalizations for clients, alongside over 100% growth in the last year and 80% average contract expansion with existing customers. Town Hall Ventures, founded in 2018, focuses on companies improving care for underserved communities and has backed firms like Cityblock Health and Landmark Health. A third-party source lists Arine's post-money valuation at $520 million as of June 2025, implying a capital efficiency ratio of 8.18x total funding raised, reflecting investor confidence in its growth, technology, and market position in AI medication management.
Aug 2022Series B111° West Capital (lead); MBX Capital; Katalyst Ventures; New Leaf Venture Partners; Super Capital Group$29M-Arine is a next-generation medication intelligence company headquartered in San Francisco that provides an AI-driven platform to optimize medication management, reduce costs, and improve patient outcomes for health plans and providers. Founded in 2017, the company had acquired health plan clients including national Blue Cross/Blue Shield, Medicaid, and Medicare Advantage plans by the time of this funding, and had expanded its staff to nearly 100 employees. In August 2022, Arine announced a $29 million Series B funding round composed of equity and debt financing, led by 111° West Capital with participation from new investors MBX Capital and New Leaf Venture Partners and continued support from Katalyst Ventures and Super Capital Group. The company reported achieving fivefold revenue growth prior to the Series A in October 2021 and demonstrated strong unit economics by delivering a 6-to-1 return on investment for clients while reducing hospitalizations by more than 40 percent. The Series B funding was intended to advance the platform's capabilities to enable value-based care at scale and expand offerings across the value-based care continuum including health plans, risk-bearing providers, and other channel partners.
Jan 2021Series A111° West Capital (lead); Katalyst Ventures (lead); SCAN Group; Magellan Health Services$11M$64MArine is a San Francisco-based AI-driven platform that optimizes medication management, reduces costs, and improves outcomes for health plans and providers. The company analyzes multi-source clinical, social, and behavioral data using thousands of algorithms to recommend personalized, just-in-time clinical interventions, saving 1 in every 6 healthcare dollars spent and serving 5.5 million patients at the time of funding. Arine combines automation with clinical services to address medication mismanagement, a key driver of healthcare inefficiencies. Arine closed an oversubscribed $11 million Series A round on October 26, 2021, co-led by 111° West Capital Partners and Katalyst Ventures, with strategic investments from Magellan Health Inc. and SCAN Group. The post-money valuation was $63.85 million. Proceeds supported scaling the team and technology platform to manage multiples of the current 5.5 million lives. 111° West Capital focuses on high-growth healthcare software companies with revenues of $5 million to $50 million, marking Arine as their first investment from a new fund. Katalyst Ventures highlighted Arine's improved patient outcomes and growth potential.

Who has invested in Arine?

9 investors have backed Arine across its funding rounds, including Katalyst Ventures, 111° West Capital, New Leaf Venture Partners, Kaiser Permanente Ventures, Town Hall Ventures and MBX Capital.

Lead investors include Town Hall Ventures, 111° West Capital and Katalyst Ventures.


Arine Investors

Investors in Arine by funding rounds participated
InvestorHQRoundsRoleFirst check
111° West CapitalUnited StatesUnited States2LeadJan 2021
Katalyst VenturesUnited StatesSan Francisco, CA2LeadJan 2021
MBX CapitalUnited StatesNew York City, NY1ParticipantAug 2022
Kaiser Permanente VenturesUnited StatesSan Francisco, CA1ParticipantMay 2025
Town Hall VenturesUnited StatesNew York City, NY1LeadMay 2025
New Leaf Venture PartnersUnited StatesNew York City, NY1ParticipantAug 2022
SCAN GroupUnited StatesLos Angeles, CA1ParticipantJan 2021

This data is available for Pro users. Sign up to see all 9 Arine investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Arine Competitors

Arine competitors include listed companies like Veradigm, Yidu Tech and Echo IQ, and private ones like Medbanks, HealthVerity and Truveta.

Public and private companies comparable to Arine
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
VeradigmUnited StatesUnited StatesPublicly listed$588M$54M$523M0.9x
Yidu TechChinaChinaPublicly listed$122M($4M)$449M1.2x
MedbanksChinaBeijingPrivate--$430M-
HealthVerityUnited StatesPhiladelphia, PAPrivate--$721M-
Echo IQAustraliaAustraliaPublicly listed$65K($13M)$311M994.2x
TruvetaUnited StatesSeattle, WAPrivate--$1B-

Arine Public Comps

Arine is still privately-owned, but its public comps include Veradigm, Claritev, Equasens, Heren Health, Shang Gong Group, Bayzed Health Group, Guiyang Longmaster, GPI Group, Medley Inc. and RaySearch Labs.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Veradigm$588M$54M0.9x0.9x9.8x6.8x
Claritev$965M$466M5.4x5.2x11.2x8.5x
Equasens$272M$75M1.9x1.8x7.0x6.7x
Heren Health$65M$11M7.4x-42.4x-
Shang Gong Group$649M$27M1.0x-23.7x-
Bayzed Health Group$167M$18M3.0x-28.4x-
Guiyang Longmaster$44M$5M10.0x-87.9x-
GPI Group$628M$117M1.4x1.4x7.3x6.5x

This data is available for Pro users. Sign up to see all Arine competitors and their valuation data.

Start Free Trial

Common questions about Arine

When was Arine founded?Arine was founded in 2017.
Where is Arine headquartered?Arine is headquartered in San Francisco, CA, United States.
Is Arine publicly listed?No, Arine is a private, VC-backed company.
What is Arine's valuation?Arine was last valued at $520M in its Series C in May 2025.
How much funding has Arine raised?Arine has raised $70M across 3 funding rounds.
What was Arine's last funding round?Arine's last funding round was a $30M Series C in May 2025, led by Town Hall Ventures.
Who are Arine's investors?Arine's investors include 111° West Capital, Katalyst Ventures, MBX Capital, Kaiser Permanente Ventures, Town Hall Ventures, New Leaf Venture Partners, SCAN Group, Magellan Health Services and Super Capital Group.
Which companies are comparable to Arine?Companies comparable to Arine include Veradigm, Yidu Tech, Medbanks, HealthVerity, Echo IQ and Truveta.

See companies similar to Arine

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial